BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

388 related articles for article (PubMed ID: 24742384)

  • 1. Influence of the adamantyl moiety on the activity of biphenylacrylohydroxamic acid-based HDAC inhibitors.
    Cincinelli R; Musso L; Giannini G; Zuco V; De Cesare M; Zunino F; Dallavalle S
    Eur J Med Chem; 2014 May; 79():251-9. PubMed ID: 24742384
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Biphenyl-4-yl-acrylohydroxamic acids: Identification of a novel indolyl-substituted HDAC inhibitor with antitumor activity.
    Cincinelli R; Zwick V; Musso L; Zuco V; De Cesare M; Zunino F; Simoes-Pires C; Nurisso A; Giannini G; Cuendet M; Dallavalle S
    Eur J Med Chem; 2016 Apr; 112():99-105. PubMed ID: 26890116
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of C7-substitution of 1-arylsulfonyl-5-(N-hydroxyacrylamide)indolines on the selectivity towards a subclass of histone deacetylases.
    Lee HY; Wang LT; Li YH; Pan SL; Chen YL; Teng CM; Liou JP
    Org Biomol Chem; 2014 Nov; 12(44):8966-76. PubMed ID: 25277250
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Design, synthesis and preliminary bioactivity studies of 1,3,4-thiadiazole hydroxamic acid derivatives as novel histone deacetylase inhibitors.
    Guan P; Sun F; Hou X; Wang F; Yi F; Xu W; Fang H
    Bioorg Med Chem; 2012 Jun; 20(12):3865-72. PubMed ID: 22579621
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Design, synthesis, and biological evaluation of indole-based hydroxamic acid derivatives as histone deacetylase inhibitors.
    Jiang BE; Hu J; Liu H; Liu Z; Wen Y; Liu M; Zhang HK; Pang X; Yu LF
    Eur J Med Chem; 2022 Jan; 227():113893. PubMed ID: 34656899
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Synthesis and antitumor activity of novel diaryl ether hydroxamic acids derivatives as potential HDAC inhibitors.
    Zhu Y; Chen X; Wu Z; Zheng Y; Chen Y; Tang W; Lu T
    Arch Pharm Res; 2012 Oct; 35(10):1723-32. PubMed ID: 23139122
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Alkyl piperidine and piperazine hydroxamic acids as HDAC inhibitors.
    Rossi C; Porcelloni M; D'Andrea P; Fincham CI; Ettorre A; Mauro S; Squarcia A; Bigioni M; Parlani M; Nardelli F; Binaschi M; Maggi CA; Fattori D
    Bioorg Med Chem Lett; 2011 Apr; 21(8):2305-8. PubMed ID: 21420859
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Identification of a series of substituted 2-piperazinyl-5-pyrimidylhydroxamic acids as potent histone deacetylase inhibitors.
    Angibaud P; Van Emelen K; Decrane L; van Brandt S; Ten Holte P; Pilatte I; Roux B; Poncelet V; Speybrouck D; Queguiner L; Gaurrand S; Mariën A; Floren W; Janssen L; Verdonck M; van Dun J; van Gompel J; Gilissen R; Mackie C; Du Jardin M; Peeters J; Noppe M; Van Hijfte L; Freyne E; Page M; Janicot M; Arts J
    Bioorg Med Chem Lett; 2010 Jan; 20(1):294-8. PubMed ID: 19906529
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Design, synthesis and anticancer activity of piperazine hydroxamates and their histone deacetylase (HDAC) inhibitory activity.
    Chetan B; Bunha M; Jagrat M; Sinha BN; Saiko P; Graser G; Szekeres T; Raman G; Rajendran P; Moorthy D; Basu A; Jayaprakash V
    Bioorg Med Chem Lett; 2010 Jul; 20(13):3906-10. PubMed ID: 20605448
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Discovery and preliminary evaluation of 2-aminobenzamide and hydroxamate derivatives containing 1,2,4-oxadiazole moiety as potent histone deacetylase inhibitors.
    Cai J; Wei H; Hong KH; Wu X; Cao M; Zong X; Li L; Sun C; Chen J; Ji M
    Eur J Med Chem; 2015; 96():1-13. PubMed ID: 25874326
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Amide-based derivatives of β-alanine hydroxamic acid as histone deacetylase inhibitors: attenuation of potency through resonance effects.
    Liao V; Liu T; Codd R
    Bioorg Med Chem Lett; 2012 Oct; 22(19):6200-4. PubMed ID: 22932316
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Development of Purine-Based Hydroxamic Acid Derivatives: Potent Histone Deacetylase Inhibitors with Marked in Vitro and in Vivo Antitumor Activities.
    Chen Y; Wang X; Xiang W; He L; Tang M; Wang F; Wang T; Yang Z; Yi Y; Wang H; Niu T; Zheng L; Lei L; Li X; Song H; Chen L
    J Med Chem; 2016 Jun; 59(11):5488-504. PubMed ID: 27186676
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Synthesis and biological characterization of spiro[2H-(1,3)-benzoxazine-2,4'-piperidine] based histone deacetylase inhibitors.
    Thaler F; Varasi M; Abate A; Carenzi G; Colombo A; Bigogno C; Boggio R; Zuffo RD; Rapetti D; Resconi A; Regalia N; Vultaggio S; Dondio G; Gagliardi S; Minucci S; Mercurio C
    Eur J Med Chem; 2013 Jun; 64():273-84. PubMed ID: 23644210
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Discovery of adamantane based highly potent HDAC inhibitors.
    Gopalan B; Ponpandian T; Kachhadia V; Bharathimohan K; Vignesh R; Sivasudar V; Narayanan S; Mandar B; Praveen R; Saranya N; Rajagopal S; Rajagopal S
    Bioorg Med Chem Lett; 2013 May; 23(9):2532-7. PubMed ID: 23538115
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pyrimidinedione-mediated selective histone deacetylase 6 inhibitors with antitumor activity in colorectal cancer HCT116 cells.
    Liu YM; Lee HY; Lai MJ; Pan SL; Huang HL; Kuo FC; Chen MC; Liou JP
    Org Biomol Chem; 2015 Oct; 13(40):10226-35. PubMed ID: 26309122
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Development of 3-hydroxycinnamamide-based HDAC inhibitors with potent in vitro and in vivo anti-tumor activity.
    Li X; Hou J; Li X; Jiang Y; Liu X; Mu W; Jin Y; Zhang Y; Xu W
    Eur J Med Chem; 2015 Jan; 89():628-37. PubMed ID: 25462271
    [TBL] [Abstract][Full Text] [Related]  

  • 17. New aryldithiolethione derivatives as potent histone deacetylase inhibitors.
    Tazzari V; Cappelletti G; Casagrande M; Perrino E; Renzi L; Del Soldato P; Sparatore A
    Bioorg Med Chem; 2010 Jun; 18(12):4187-94. PubMed ID: 20576572
    [TBL] [Abstract][Full Text] [Related]  

  • 18. New benzothiazole/thiazole-containing hydroxamic acids as potent histone deacetylase inhibitors and antitumor agents.
    Tung TT; Oanh DT; Dung PT; Hue VT; Park SH; Han BW; Kim Y; Hong JT; Han SB; Nam NH
    Med Chem; 2013 Dec; 9(8):1051-7. PubMed ID: 23521008
    [TBL] [Abstract][Full Text] [Related]  

  • 19. 1-Aroylindoline-hydroxamic acids as anticancer agents, inhibitors of HSP90 and HDAC.
    Ojha R; Huang HL; HuangFu WC; Wu YW; Nepali K; Lai MJ; Su CJ; Sung TY; Chen YL; Pan SL; Liou JP
    Eur J Med Chem; 2018 Apr; 150():667-677. PubMed ID: 29567459
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Quinolone-based HDAC inhibitors.
    Balasubramanian G; Kilambi N; Rathinasamy S; Rajendran P; Narayanan S; Rajagopal S
    J Enzyme Inhib Med Chem; 2014 Aug; 29(4):555-62. PubMed ID: 25019596
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.